Form 4: Enanta Pharma Officer Forfeits Shares for Tax
Insider Transaction Report
Enanta Pharmaceuticals' Chief Product Strategy Officer, Tara Lynn Kieffer, reported a future forfeiture of 753 common shares to cover tax withholdings related to a restricted stock unit settlement.
Summary
- Tara Lynn Kieffer, Chief Product Strategy Officer of Enanta Pharmaceuticals Inc. (ENTA), filed a Form 4.
- The filing reports a planned transaction on December 1, 2025, where 753 shares of common stock will be forfeited.
- This forfeiture is to cover withholding taxes due to the settlement of a portion of a restricted stock unit (RSU) award.
- The RSU award was originally granted on November 19, 2021.
- The shares were valued at $14.12 per share for the purpose of this transaction.
- Following this transaction, Ms. Kieffer will beneficially own 32,726 shares of Enanta Pharmaceuticals common stock directly.
- The transaction is made pursuant to a Rule 10b5-1(c) plan, indicating it was pre-arranged.
Sentiment
Score: 5
Explanation: The filing reports a routine, pre-planned insider transaction for tax withholding purposes related to equity compensation. This type of transaction is neutral and does not indicate any positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
The filing details a pre-planned future transaction related to executive compensation, specifically a tax withholding event scheduled for December 1, 2025. It does not provide any forward-looking statements regarding company performance or strategic direction.
Industry Context
This filing is a routine insider transaction report common in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors like Enanta Pharmaceuticals, where equity compensation such as Restricted Stock Units (RSUs) is a standard component of executive remuneration. The forfeiture of shares for tax purposes upon RSU vesting is a common and expected event.
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, small-scale transaction related to executive compensation and tax compliance, not a discretionary sale or purchase that would signal a change in insider sentiment or company fundamentals.
Key Dates
| Date | Description |
|---|---|
| November 19, 2021 | Date of original restricted stock unit (RSU) award grant. |
| December 1, 2025 | Transaction date for the forfeiture of common stock to cover withholding taxes. |
| December 3, 2025 | Date the Form 4 was signed and filed. |
Keywords
Enanta Pharmaceuticals, ENTA, Form 4, Insider Transaction, Restricted Stock Unit, RSU, Tax Withholding, Equity Compensation, Tara Lynn Kieffer, Chief Product Strategy Officer, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.